GoAI
Get started
Joyzyme Group Limited logo

Joyzyme Group Limited

8622.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$0.164

HK$0.00 · 0.00%

Aug 24, 11:04 AM HKTData delayed

8622.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
HK
CEO
Chunguang Zhang
Listed since
Dec 13, 2018
Employees
101

Market position

52-week range

Current HK$0.164

Open
HK$0.164
Previous close
HK$0.164
Volume
112K
0.47× average
Average volume
240.36K
Average daily volume
Market cap
84.54M HKD
Beta
0.72
Market reference 1
50-day average
HK$0.1834
-10.58% below average
200-day average
HK$0.3199
-48.73% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
163.93M CNY
P/E (TTM)
-14.07×
P/B (TTM)
1.38×
P/S (TTM)
2.56×
EV / EBITDA
-26.57×
Earnings yield
-2.56%
Free cash flow yield
-1.68%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
62.83%
Operating margin
-30.29%
Net margin
-17.70%
Return on equity
-9.79%
Return on assets
-7.51%
Return on invested capital
-13.91%

Financial health

Debt / equity
0.1×
Current ratio
3.88×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends77%38%-1%-40%Gross margin, FY2021: 62.98%Gross margin, FY2022: 66.77%Gross margin, FY2023: 65.34%Gross margin, FY2024: 67.32%Gross margin, FY2025: 62.83%Operating margin, FY2021: -17.52%Operating margin, FY2022: -20.09%Operating margin, FY2023: -30.01%Operating margin, FY2024: -19.76%Operating margin, FY2025: -27.61%Net margin, FY2021: -16.15%Net margin, FY2022: -12.14%Net margin, FY2023: -23.48%Net margin, FY2024: -16.40%Net margin, FY2025: -17.70%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 62.98%. Gross margin FY2022 66.77%. Gross margin FY2023 65.34%. Gross margin FY2024 67.32%. Gross margin FY2025 62.83%. Operating margin FY2021 -17.52%. Operating margin FY2022 -20.09%. Operating margin FY2023 -30.01%. Operating margin FY2024 -19.76%. Operating margin FY2025 -27.61%. Net margin FY2021 -16.15%. Net margin FY2022 -12.14%. Net margin FY2023 -23.48%. Net margin FY2024 -16.40%. Net margin FY2025 -17.70%.

Income trends

Revenue

28.28M CNY+11.53%

Operating income

−7.81M CNY-55.86%

Net income

−5.01M CNY-20.39%
Income trends across reported periods31.89M CNY17.45M CNY3.02M CNY−11.42M CNYRevenue, FY2021: 26.13M CNYRevenue, FY2022: 25.33M CNYRevenue, FY2023: 24.63M CNYRevenue, FY2024: 25.36M CNYRevenue, FY2025: 28.28M CNYOperating income, FY2021: −4.58M CNYOperating income, FY2022: −5.09M CNYOperating income, FY2023: −7.39M CNYOperating income, FY2024: −5.01M CNYOperating income, FY2025: −7.81M CNYNet income, FY2021: −4.22M CNYNet income, FY2022: −3.08M CNYNet income, FY2023: −5.78M CNYNet income, FY2024: −4.16M CNYNet income, FY2025: −5.01M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 26.13M CNY. Revenue FY2022 25.33M CNY. Revenue FY2023 24.63M CNY. Revenue FY2024 25.36M CNY. Revenue FY2025 28.28M CNY. Operating income FY2021 −4.58M CNY. Operating income FY2022 −5.09M CNY. Operating income FY2023 −7.39M CNY. Operating income FY2024 −5.01M CNY. Operating income FY2025 −7.81M CNY. Net income FY2021 −4.22M CNY. Net income FY2022 −3.08M CNY. Net income FY2023 −5.78M CNY. Net income FY2024 −4.16M CNY. Net income FY2025 −5.01M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue28.28M CNY25.36M CNY24.63M CNY25.33M CNY26.13M CNY
Cost of goods sold10.51M CNY8.29M CNY8.54M CNY8.42M CNY9.67M CNY
Gross profit17.77M CNY17.07M CNY16.09M CNY16.91M CNY16.46M CNY
Research and development3.93M CNY2.83M CNY2.55M CNY2.48M CNY2.44M CNY
Selling, general, and administrative22.41M CNY19.26M CNY18.49M CNY18.75M CNY17.7M CNY
Operating expenses26.34M CNY22.08M CNY23.48M CNY22M CNY20.24M CNY
Interest income315.61K CNY512K CNY404K CNY409K CNY179K CNY
Interest expense239.63K CNY86K CNY53K CNY55K CNY102K CNY
Depreciation and amortization1.72M CNY1.6M CNY3.18M CNY3.14M CNY2.95M CNY
Operating income−7.81M CNY−5.01M CNY−7.39M CNY−5.09M CNY−4.58M CNY
Net income−5.01M CNY−4.16M CNY−5.78M CNY−3.08M CNY−4.22M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0-0.02-0.03-0.05Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25
Q2 2023, reported May 13, 2023: actual -0.001, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 10, 2023: actual -0.002, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 14, 2023: actual -0.003, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 29, 2024: actual -0.009, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 14, 2024: actual -0.002, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 16, 2024: actual -0.002, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 15, 2024: actual -0.003, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual -0.003, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates7.89M7.22M6.54M5.86MQ2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25
Q2 2023, reported May 13, 2023: actual 6.58M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 10, 2023: actual 6.17M HKD, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 14, 2023: actual 6.77M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 29, 2024: actual 7.59M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 14, 2024: actual 6.45M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 16, 2024: actual 6.4M HKD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 15, 2024: actual 7.44M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 7.15M HKD, estimate —, surprise —, Comparison unavailable.

8622.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.8

-3.89%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.74

-3.03%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.4

-2.46%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.22

-5.62%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.2

-2.15%

Continue in GoAI

Research 8622.HK

research.disclaimer